Impact of high-risk features for stage II adenocarcinoma of the appendix

Impact of high-risk features for stage II adenocarcinoma of the appendix

Clinico-pathological high-risk features are frequently utilized in adjuvant chemotherapy (AC) decisions in stage II colorectal cancer and their utility in stage II appendiceal adenocarcinoma (AA) is not established. The aim of this study is to determine the impact of high-risk features in clinical o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer treatment and research communications 2021, Vol.27, p.100329-100329, Article 100329
Hauptverfasser: Akce, Mehmet, Zakka, Katerina, Penley, McKenna, Jiang, Renjian, Khalil, Lana, Alese, Olatunji B., Shaib, Walid L., Wu, Christina, Behera, Madhusmita, El-Rayes, Bassel F.
Format: Artikel
Sprache:eng
Schlagworte:
Adenocarcinoma - diagnosis
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Adjuvant chemotherapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Appendectomy
Appendiceal Neoplasms - diagnosis
Appendiceal Neoplasms - mortality
Appendiceal Neoplasms - pathology
Appendiceal Neoplasms - therapy
Appendix - pathology
Appendix - surgery
Appendix adenocarcinoma
Chemotherapy
Chemotherapy, Adjuvant - methods
Chemotherapy, Adjuvant - statistics & numerical data
Clinical outcomes
Female
High risk
Humans
Kaplan-Meier Estimate
Low risk
Male
Margins of Excision
Middle Aged
Neoplasm Staging
Retrospective Studies
Risk Assessment - methods
Risk Factors
Stage II
Treatment
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Clinico-pathological high-risk features are frequently utilized in adjuvant chemotherapy (AC) decisions in stage II colorectal cancer and their utility in stage II appendiceal adenocarcinoma (AA) is not established. The aim of this study is to determine the impact of high-risk features in clinical outcomes and whether high risk features are predictive of AC benefit in stage II AA. Patients with pathological stage II AA between 2010 and 2015 were identified from the National Cancer Database (NCDB) using ICD-O-3 morphology and topography codes: 8140, 8480 and C18.1. High risk stage II AA was defined as having at least one of the following clinicopathological features: T4 tumor,
ISSN:2468-2942
2468-2942
DOI:10.1016/j.ctarc.2021.100329